Research progress of pomalidomide in the treatment of relapsed refractory multiple myeloma

Songlin Chu; Liansheng Zhang

doi:10.3760/cma.j.issn.l009-9921.2014.03.017

Research progress of pomalidomide in the treatment of relapsed refractory multiple myeloma

Songlin Chu, Liansheng Zhang^*

^*Corresponding author for this work

Lanzhou University

Research output: Contribution to journal › Review article › peer-review

Abstract

Pomalidomide,which represents a new generation of immunomodulatory drugs (IMiD), has brought a major shift in therapeutic paradigm in treating relapsed and refractory multiple myeloma (RRMM). Considering its encouraging effectiveness, the U.S. Food and Drug Administration (FDA) approved its usage to treat patients who fail to respond to at least two prior therapies, including lenalidomide and bortezomib, and whose disease progressed within 60 days of the last treatment. This review summarizes the mechanisms of action and clinical activity of pomalidomide in treating RRMM.

Original language	English
Pages (from-to)	179-181
Number of pages	3
Journal	Journal of Leukemia and Lymphoma
Volume	23
Issue number	3
DOIs	https://doi.org/10.3760/cma.j.issn.l009-9921.2014.03.017
Publication status	Published - 2014
Externally published	Yes

Keywords

Immunomodulatory drugs
Multiple myeloma
Pomalidomide

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3760/cma.j.issn.l009-9921.2014.03.017

Cite this

@article{9877f1e952894437b4a87f9e3c340df3,

title = "Research progress of pomalidomide in the treatment of relapsed refractory multiple myeloma",

abstract = "Pomalidomide,which represents a new generation of immunomodulatory drugs (IMiD), has brought a major shift in therapeutic paradigm in treating relapsed and refractory multiple myeloma (RRMM). Considering its encouraging effectiveness, the U.S. Food and Drug Administration (FDA) approved its usage to treat patients who fail to respond to at least two prior therapies, including lenalidomide and bortezomib, and whose disease progressed within 60 days of the last treatment. This review summarizes the mechanisms of action and clinical activity of pomalidomide in treating RRMM.",

keywords = "Immunomodulatory drugs, Multiple myeloma, Pomalidomide",

author = "Songlin Chu and Liansheng Zhang",

year = "2014",

doi = "10.3760/cma.j.issn.l009-9921.2014.03.017",

language = "English",

volume = "23",

pages = "179--181",

journal = "Journal of Leukemia and Lymphoma",

issn = "1009-9921",

publisher = "Chinese Medical Journals Publishing House Co.Ltd",

number = "3",

}

TY - JOUR

T1 - Research progress of pomalidomide in the treatment of relapsed refractory multiple myeloma

AU - Chu, Songlin

AU - Zhang, Liansheng

PY - 2014

Y1 - 2014

N2 - Pomalidomide,which represents a new generation of immunomodulatory drugs (IMiD), has brought a major shift in therapeutic paradigm in treating relapsed and refractory multiple myeloma (RRMM). Considering its encouraging effectiveness, the U.S. Food and Drug Administration (FDA) approved its usage to treat patients who fail to respond to at least two prior therapies, including lenalidomide and bortezomib, and whose disease progressed within 60 days of the last treatment. This review summarizes the mechanisms of action and clinical activity of pomalidomide in treating RRMM.

AB - Pomalidomide,which represents a new generation of immunomodulatory drugs (IMiD), has brought a major shift in therapeutic paradigm in treating relapsed and refractory multiple myeloma (RRMM). Considering its encouraging effectiveness, the U.S. Food and Drug Administration (FDA) approved its usage to treat patients who fail to respond to at least two prior therapies, including lenalidomide and bortezomib, and whose disease progressed within 60 days of the last treatment. This review summarizes the mechanisms of action and clinical activity of pomalidomide in treating RRMM.

KW - Immunomodulatory drugs

KW - Multiple myeloma

KW - Pomalidomide

UR - http://www.scopus.com/inward/record.url?scp=84897104262&partnerID=8YFLogxK

U2 - 10.3760/cma.j.issn.l009-9921.2014.03.017

DO - 10.3760/cma.j.issn.l009-9921.2014.03.017

M3 - Review article

AN - SCOPUS:84897104262

SN - 1009-9921

VL - 23

SP - 179

EP - 181

JO - Journal of Leukemia and Lymphoma

JF - Journal of Leukemia and Lymphoma

IS - 3

ER -

Research progress of pomalidomide in the treatment of relapsed refractory multiple myeloma

Abstract

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this